Genmab AS (GMAB)

35.93
-0.34(-0.94%)
Pre Market
35.83
-0.10(-0.28%)
- Real-time Data
  • Volume:
    485,934
  • Day's Range:
    35.47 - 36.04
  • 52 wk Range:
    26.19 - 49.07

GMAB Overview

Prev. Close
36.27
Day's Range
35.47-36.04
Revenue
10.21B
Open
35.84
52 wk Range
26.19-49.07
EPS
60.54
Volume
485,934
Market Cap
23.4B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
637,816
P/E Ratio
44.16
Beta
0.638
1-Year Change
-22.7%
Shares Outstanding
65,327,893
Next Earnings Date
Nov 09, 2022
What is your sentiment on Genmab AS?
or
Market is currently closed. Voting is open during market hours.

Genmab AS News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Genmab AS Analysis

Genmab AS Company Profile

Genmab AS Company Profile

Employees
1136

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellBuyStrong Buy
Technical IndicatorsStrong SellStrong BuyStrong SellBuyNeutral
SummaryNeutralNeutralStrong SellBuyBuy
  • ERs are out https://ir.genmab.com/financial-calendar
    0
    • And no debt, $3B cash position, one of the most "trending" technologies around (bispecific antibodies) and an impressive outflux of new drugs via seemingly peerpoor (now that's a nice new word - you're free to use it;-) quality of research. I urge everyone to check it out - heres the Investor Presentation for Q22021 "https://ir.genmab.com/static-files/cac2e584-6554-4637-a367-a5d21abc51e0". Comp value 2day $30B, best realistic ;-) guess is double up in 3-4 yrs. Seriously.
      0
      • Falling.. standard market reaction these days to good and solid reportings: crazy that is.. in spite of improved revenue outlook, 4 drugs on market (darazalex(need I say more?)+3 soon-to-become-blockbusters) + 1 prob-to-market-in-october (tisotumab vedotin, w Seagen) + 2 new drugs revealed (one of which: inclacumab - a Sickle Cell Disease treatment, outlicensed to Roche and further outlicensed to Global Blood Therapeutics, but none the less - w potential for BB).
        0
        • 32, 40 again soon
          0
          • Luxus
            0
            • Going 200 % up in the next 24-30 month
              0
              • what about this stock?
                0
                • The best upcoming medico company for cancer
                  0